GOG 3007, a randomized phase II (RP2) trial of everolimus and letrozole (EL) or hormonal therapy (medroxyprogesterone acetate/tamoxifen, PT) in women with advanced, persistent or recurrent endometrial carcinoma (EC): A GOG Foundation study
Slomovitz, B.M., Filiaci, V.L., Coleman, R.L., Walker, J.L., Fleury, A.C., Holman, L.L., Miller, D.S.Volume:
149
Language:
english
Journal:
Gynecologic Oncology
DOI:
10.1016/j.ygyno.2018.04.012
Date:
June, 2018
File:
PDF, 193 KB
english, 2018